Saturday 17 October 2026
Export PBYI’s income statement to Excel — free account
Puma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.83
0.69
−6.56%
Follow PBYI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
7.08 | 9.44 | 12.78 | 15.02 |
P/S ratio |
1.26 | 1.30 | 1.43 | 1.79 | |
P/FCF ratio |
8.80 | 10.18 | 7.92 | 14.46 | |
P/Operating CF |
27.59 | 20.64 | 21.08 | 254.39 | |
P/B ratio |
2.32 | 2.28 | 2.53 | 2.98 | |
Price to Tangible BV |
3.74 | 3.35 | 3.63 | 4.05 | |
EV/Sales |
1.02 | 1.01 | 1.07 | 1.48 | |
EV/EBITDA |
4.82 | 4.80 | 6.05 | 8.34 | |
EV/Operating CF |
5.01 | 5.53 | 4.54 | 8.30 | |
EV/FCF |
7.09 | 7.91 | 5.93 | 11.95 | |
Quick Ratio |
1.57 | 1.89 | 2.18 | 2.57 | |
Current Ratio |
1.74 | 2.00 | 2.38 | 2.91 | |
Net Debt/EBITDA |
(5.10) | (3.90) | 74.24 | (9.30) | |
Debt/Assets |
16.62% | 10.41% | 5.86% | 0.00% | |
Debt/Equity |
0.29 | 0.17 | 0.09 | 0.00 | |
Asset Turnover |
1.00 | 1.06 | 1.17 | 1.19 | |
Operating CF/Net income |
1.10 | 1.07 | (4.11) | 0.20 | |
Capex/Depreciation |
(0.01) | 0.01 | 0.00 | 0.00 | |
Interest Coverage |
6.43 | 15.29 | (5.24) | 42.14 | |
Research and Development Expense of Revenue |
29.21% | 22.32% | 44.17% | 33.44% | |
Selling, General and Administrative Expense of Revenue |
30.87% | 24.36% | 41.11% | 31.06% | |
Intangible Assets out of Total Assets |
0.22 | 0.19 | 0.20 | 0.19 | |
Share Based Compensation of Revenue |
3.07% | 2.14% | 4.23% | 3.46% | |
Graham Net Nets |
0.21 | 0.26 | 0.24 | 0.22 | |
Graham Number |
6.22 | 6.08 | 5.33 | 5.75 | |
Earnings Yield |
14.12% | 10.59% | 7.82% | 6.66% | |
Free Cash Flow Yield |
11.36% | 9.82% | 12.63% | 6.92% | |
Revenue per Share |
1.08 | 1.51 | 0.88 | 1.11 | |
Operating CF per Share |
0.19 | 0.29 | 0.30 | 0.03 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.19 | 0.29 | 0.30 | 0.03 | |
Cash per Share |
1.92 | 1.99 | 2.04 | 1.84 | |
Shareholders Equity per Share |
2.29 | 2.61 | 2.53 | 2.72 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.29 | 2.61 | 2.53 | 2.72 | |
Free Cash Flow |
9.66 | 14.46 | 15.42 | 1.62 | |
Working Capital |
60.85 | 81.43 | 82.52 | 95.25 | |
Capital Expenditures |
(0.03) | 0.04 | — | — | |
Net Current Asset Value |
55.99 | 76.72 | 77.98 | 90.88 | |
EV/EBIT |
6.42 | 6.20 | 8.26 | 11.22 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
7.97 | 7.98 | 11.02 | 13.57 | |
| Other line items | |||||
Average Receivables |
44.10 | 42.83 | 25.75 | 29.99 | |
Average Payables |
6.95 | 5.28 | 7.10 | 4.26 | |
Average Inventory |
6.07 | 7.12 | 8.72 | 10.96 | |
Average Assets |
211.79 | 214.82 | 194.44 | 193.83 | |
Average Common Equity |
93.18 | 111.23 | 112.76 | 121.63 |
Columns are period end dates